People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Galvanize Therapeutics, Inc. | — | Biotechnology | Series C | $150.7M | $581.7M | 2015 |
| HeartWare International, Inc. | — | Other Health Care | Series C | $55.2M | $5.0M | 2009 |
| Tusker Medical, Inc. | — | Biotechnology | Series B | $53.5M | $79.4M | 2016 |
| Vdyne, Inc. | — | Biotechnology | Series A | $33.0M | $233.7M | 2019 |
| QDP TopCo LLC | — | Other Health Care | Series B | $31.8M | $704.5M | 2016 |
David McIntyre at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David McIntyre on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 3 | 19 |
| Robert Thomas | 1 | 8 |
| Amir Abolfathi | 1 | 8 |
| David Lewis | 1 | 7 |
| Sami Hamade | 1 | 6 |
| ANTOINE PAPIERNIK | 1 | 6 |
| Timothy Barberich | 1 | 6 |
| Renee Ryan | 1 | 6 |
| David Schuppan | 1 | 5 |
| Douglas Godshall | 1 | 4 |
| Jonathan Waldstreicher | 1 | 3 |
| Zack Scott | 1 | 3 |
| Doug Godshall | 1 | 3 |
| Ralph Davis | 1 | 3 |
| Greg Pearl | 1 | 2 |
| Edward W. Malouf | 1 | 2 |
| Timothy A. Barberich | 1 | 2 |
| Diane Daych | 1 | 2 |
| Gene Fleming | 1 | 2 |
| Robert A Thomas | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.